Trials / No Longer Available
No Longer AvailableNCT04087876
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Expanded Access Use of Derazantinib for Patients With Locally Advanced, Inoperable or Metastatic iCCA Harbouring FGFR Genomic Alterations
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Basilea Pharmaceutica · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Basilea provided expanded access to derazantinib for patients with locally advanced, inoperable or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR genomic alterations on a patient by patient basis while clinical development of derazantinib was ongoing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | derazantinib | derazantinib will be administered orally |
Timeline
- First posted
- 2019-09-12
- Last updated
- 2025-04-06
Source: ClinicalTrials.gov record NCT04087876. Inclusion in this directory is not an endorsement.